115 related articles for article (PubMed ID: 30037283)
21. Understanding the cross-resistance of oseltamivir to H1N1 and H5N1 influenza A neuraminidase mutations using multidimensional computational analyses.
Singh A; Soliman ME
Drug Des Devel Ther; 2015; 9():4137-54. PubMed ID: 26257512
[TBL] [Abstract][Full Text] [Related]
22. Quantitative structure activity relationship studies on thiourea analogues as influenza virus neuraminidase inhibitors.
Nair PC; Sobhia ME
Eur J Med Chem; 2008 Feb; 43(2):293-9. PubMed ID: 17513019
[TBL] [Abstract][Full Text] [Related]
23. The chemiluminescent neuraminidase inhibition assay: a functional method for detection of influenza virus resistance to the neuraminidase inhibitors.
Okomo-Adhiambo M; Hurt AC; Gubareva LV
Methods Mol Biol; 2012; 865():95-113. PubMed ID: 22528155
[TBL] [Abstract][Full Text] [Related]
24. A QSAR study on influenza neuraminidase inhibitors.
Verma RP; Hansch C
Bioorg Med Chem; 2006 Feb; 14(4):982-96. PubMed ID: 16213733
[TBL] [Abstract][Full Text] [Related]
25. Using kernel alignment to select features of molecular descriptors in a QSAR study.
Wong WW; Burkowski FJ
IEEE/ACM Trans Comput Biol Bioinform; 2011; 8(5):1373-84. PubMed ID: 21339534
[TBL] [Abstract][Full Text] [Related]
26. Docking and 3D QSAR study of thiourea analogs as potent inhibitors of influenza virus neuraminidase.
Sun J; Cai S; Mei H; Li J; Yan N; Wang Y
J Mol Model; 2010 Dec; 16(12):1809-18. PubMed ID: 20213331
[TBL] [Abstract][Full Text] [Related]
27. [Prediction of selective inhibition of neuraminidase from various influenza virus strains by potential inhibitors].
Mikurova AV; Rybina AV; Skvortsov VS
Biomed Khim; 2016 Nov; 62(6):691-703. PubMed ID: 28026814
[TBL] [Abstract][Full Text] [Related]
28. Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan.
Dapat C; Kondo H; Dapat IC; Baranovich T; Suzuki Y; Shobugawa Y; Saito K; Saito R; Suzuki H
Antiviral Res; 2013 Sep; 99(3):261-9. PubMed ID: 23791870
[TBL] [Abstract][Full Text] [Related]
29. Pharmacophore modeling, 3D-QSAR studies, and in-silico ADME prediction of pyrrolidine derivatives as neuraminidase inhibitors.
Zhang J; Pan X; Wang C; Wang F; Li P; Xu W; He L
Chem Biol Drug Des; 2012 Mar; 79(3):353-9. PubMed ID: 22222003
[TBL] [Abstract][Full Text] [Related]
30. [Creation of a generalized model prediction of inhibition of neuraminidase of influenza virus of various strains].
Mikurova AV; Skvortsov VS
Biomed Khim; 2018 Jun; 64(3):247-252. PubMed ID: 29964260
[TBL] [Abstract][Full Text] [Related]
31. Antiviral activity of baicalin against influenza A (H1N1/H3N2) virus in cell culture and in mice and its inhibition of neuraminidase.
Ding Y; Dou J; Teng Z; Yu J; Wang T; Lu N; Wang H; Zhou C
Arch Virol; 2014 Dec; 159(12):3269-78. PubMed ID: 25078390
[TBL] [Abstract][Full Text] [Related]
32. Descriptor Selection Improvements for Quantitative Structure-Activity Relationships.
Xia LY; Wang QY; Cao Z; Liang Y
Int J Neural Syst; 2019 Nov; 29(9):1950016. PubMed ID: 31390912
[TBL] [Abstract][Full Text] [Related]
33. Theoretical studies on the susceptibility of oseltamivir against variants of 2009 A/H1N1 influenza neuraminidase.
Li L; Li Y; Zhang L; Hou T
J Chem Inf Model; 2012 Oct; 52(10):2715-29. PubMed ID: 22998323
[TBL] [Abstract][Full Text] [Related]
34. Improving virtual screening predictive accuracy of Human kallikrein 5 inhibitors using machine learning models.
Fang X; Bagui S; Bagui S
Comput Biol Chem; 2017 Aug; 69():110-119. PubMed ID: 28601761
[TBL] [Abstract][Full Text] [Related]
35. Novel oral anti-influenza drug candidate AV5080.
Ivachtchenko AV; Ivanenkov YA; Mitkin OD; Yamanushkin PM; Bichko VV; Shevkun NA; Karapetian RN; Leneva IA; Borisova OV; Veselov MS
J Antimicrob Chemother; 2014 Jul; 69(7):1892-902. PubMed ID: 24729605
[TBL] [Abstract][Full Text] [Related]
36. Complexity in influenza virus targeted drug design: interaction with human sialidases.
Chavas LM; Kato R; Suzuki N; von Itzstein M; Mann MC; Thomson RJ; Dyason JC; McKimm-Breschkin J; Fusi P; Tringali C; Venerando B; Tettamanti G; Monti E; Wakatsuki S
J Med Chem; 2010 Apr; 53(7):2998-3002. PubMed ID: 20222714
[TBL] [Abstract][Full Text] [Related]
37. The fluorescence neuraminidase inhibition assay: a functional method for detection of influenza virus resistance to the neuraminidase inhibitors.
Hurt AC; Okomo-Adhiambo M; Gubareva LV
Methods Mol Biol; 2012; 865():115-25. PubMed ID: 22528156
[TBL] [Abstract][Full Text] [Related]
38. Hyphenated 3D-QSAR statistical model-drug repurposing analysis for the identification of potent neuraminidase inhibitor.
Rohini K; Shanthi V
Cell Biochem Biophys; 2018 Sep; 76(3):357-376. PubMed ID: 29687225
[TBL] [Abstract][Full Text] [Related]
39. Exploring the cause of oseltamivir resistance against mutant H274Y neuraminidase by molecular simulation approach.
Karthick V; Shanthi V; Rajasekaran R; Ramanathan K
Appl Biochem Biotechnol; 2012 May; 167(2):237-49. PubMed ID: 22544690
[TBL] [Abstract][Full Text] [Related]
40. Comparison between virus shedding and fever duration after treating children with pandemic A H1N1/09 and children with A H3N2 with a neuraminidase inhibitor.
Sugaya N; Sakai-Tagawa Y; Bamba M; Yasuhara R; Yamazaki M; Kawakami C; Yamaguchi Y; Ide Y; Ichikawa M; Mitamura K; Kawaoka Y
Antivir Ther; 2015; 20(1):49-55. PubMed ID: 24832015
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
